Tango Therapeutics Gets FDA OK for Cancer-Drug Trial
24 Janeiro 2022 - 9:51AM
Dow Jones News
By Matt Grossman
Tango Therapeutics Inc. said Monday that the U.S. Food and Drug
Administration has cleared its investigational-new-drug application
for TNG908, a drug designed to selectively kill cancer cells.
The FDA action would allow Tango to proceed with a Phase 1/2
clinical trial, set to begin in the first half of this year.
Preliminary safety and efficacy data would likely be available in
the first half of 2023, Tango said.
The study will evaluate the drug's use in patients with
MTAP-deleted tumors.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
January 24, 2022 07:36 ET (12:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
